These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31729943)

  • 1. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
    Gao F; Yang C
    Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CXCR4-dependent immunosuppressive Ly6C
    Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
    Hamerlik P; Lathia JD; Rasmussen R; Wu Q; Bartkova J; Lee M; Moudry P; Bartek J; Fischer W; Lukas J; Rich JN; Bartek J
    J Exp Med; 2012 Mar; 209(3):507-20. PubMed ID: 22393126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
    Wentink MQ; Broxterman HJ; Lam SW; Boven E; Walraven M; Griffioen AW; Pili R; van der Vliet HJ; de Gruijl TD; Verheul HM
    Br J Cancer; 2016 Oct; 115(8):940-948. PubMed ID: 27575850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
    Eguchi R; Kawabe JI; Wakabayashi I
    J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.
    Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST
    Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinations of Bevacizumab With Cancer Immunotherapy.
    Chen DS; Hurwitz H
    Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
    Allen E; Jabouille A; Rivera LB; Lodewijckx I; Missiaen R; Steri V; Feyen K; Tawney J; Hanahan D; Michael IP; Bergers G
    Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
    Yasuda S; Sho M; Yamato I; Yoshiji H; Wakatsuki K; Nishiwada S; Yagita H; Nakajima Y
    Clin Exp Immunol; 2013 Jun; 172(3):500-6. PubMed ID: 23600839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
    Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
    Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
    Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
    Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
    Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
    PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
    Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
    Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
    J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.